IGI Logo

Alkem Laboratories is currently trading at Rs. 6213.50, up by 77.50 points or 1.26% from its previous closing of Rs. 6136.00 on the BSE.

The scrip opened at Rs. 6160.00 and has touched a high and low of Rs. 6222.45 and Rs. 6136.80 respectively. So far 686 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 6440.00 on 17-Sep-2024 and a 52 week low of Rs. 3509.60 on 26-Oct-2023.

Last one week high and low of the scrip stood at Rs. 6369.00 and Rs. 6075.00 respectively. The current market cap of the company is Rs. 74369.43 crore.

The promoters holding in the company stood at 56.38%, while Institutions and Non-Institutions held 27.26% and 16.36% respectively.

Alkem Laboratories has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc (Sonnet) to develop, manufacture and commercialise the drug candidate ‘SON-080’ for the treatment of diabetic peripheral neuropathy in India. ‘SON-080’ is Sonnet’s proprietary version of ‘atexakin alfa’. It has shown encouraging data in phase 1b clinical trial. The drug candidate was demonstrated to be well-tolerated and the pain and quality of life survey results suggested a potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability, compared to placebo controls.

Under the licensing agreement, the company will carry out the clinical development of ‘SON-080’ in India with support from Sonnet and enable global and India regulatory filings. The company has exclusive rights to develop, manufacture and commercialise the drug in India.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.